How much funding has Longboard Pharmaceuticals raised?

Longboard Pharmaceuticals has raised $56.0M in total funding, most recently a Series A round.

Who are Longboard Pharmaceuticals's investors?

Longboard Pharmaceuticals's investors include Lundbeck A/S, Farallon Capital.

When was Longboard Pharmaceuticals founded?

Longboard Pharmaceuticals was founded in 2020.

Where is Longboard Pharmaceuticals headquartered?

Longboard Pharmaceuticals is headquartered in La Jolla, United States.

What industry is Longboard Pharmaceuticals in?

Longboard Pharmaceuticals operates in Biotech, Healthcare.

Longboard Pharmaceuticals

Acquired

The Next Wave of Neurological Medicines is Here

La Jolla, United States · Founded 2020 · $56.0M raised

Biotech

Healthcare

Headquarters: La Jolla
Founded: 2020
Business Model: B2B
Website: longboardpharma.com

Total Funding: $56.0M
Last Round: $56.0M Series AOct 2020
Rounds: 1

About

Longboard Pharmaceuticals was a clinical-stage biopharmaceutical company developing transformative medicines for neurological and rare diseases, leveraging 20 years of G protein-coupled receptor (GPCR) research originating from Arena Pharmaceuticals. Headquartered in La Jolla, California, the company was acquired by H. Lundbeck A/S in a transaction that closed on December 2, 2024, and now operates as a wholly owned subsidiary of Lundbeck.

Summary

Longboard Pharmaceuticals is a Biotech company based in La Jolla, United States, founded in 2020. It has raised $56.0M in total across 1 round, most recently a $56.0M Series A round in Oct 2020. Investors include Lundbeck A/S and Farallon Capital.